---
figid: PMC9514453__fphar-13-982238-g003
figtitle: Regulatory mechanism and potential application of IL-23 in autoimmune diseases
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC9514453
filename: fphar-13-982238-g003.jpg
figlink: /pmc/articles/PMC9514453/figure/F3/
number: F3
caption: Targeting IL-23 in autoimmune diseases. IL-23 inhibitors have been shown
  to be effective. Ustekinumab is an inhibitor targeting IL-23p40, Guselkumab and
  Risankizumab are specific inhibitors targeting IL-23p19. They each block the IL-23
  signaling pathway by binding to the p40 subunit and p19 subunit, thereby inhibiting
  the immune response of TH17.
papertitle: The regulatory mechanism and potential application of IL-23 in autoimmune
  diseases.
reftext: De-Kai Xiong, et al. Front Pharmacol. 2022;13:982238.
year: '2022'
doi: 10.3389/fphar.2022.982238
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media S.A.
keywords: IL-23 | IL-23R | IL-23/TH17 axis | autoimmune diseases | RA
automl_pathway: 0.960282
figid_alias: PMC9514453__F3
figtype: Figure
redirect_from: /figures/PMC9514453__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9514453__fphar-13-982238-g003.html
  '@type': Dataset
  description: Targeting IL-23 in autoimmune diseases. IL-23 inhibitors have been
    shown to be effective. Ustekinumab is an inhibitor targeting IL-23p40, Guselkumab
    and Risankizumab are specific inhibitors targeting IL-23p19. They each block the
    IL-23 signaling pathway by binding to the p40 subunit and p19 subunit, thereby
    inhibiting the immune response of TH17.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL9
  - RPSA
  - MAPK1
  - PSMD7
  - TP63
  - ARHGEF2
  - RABEPK
  - LANCL1
  - EBNA1BP2
  - BRMS1L
  - ARMH1
  - H3P28
  - CDKN2A
  - CDKN2D
  - F9
  - REG1A
  - IL23A
  - H3P13
  - IL37
  - IL23R
---
